1.. Introduction {#s1}
================

A malignant tumour is formed of a group of cancer cells that have the ability to grow and invade tissues either surrounding or at distant areas of the body \[[@RSOS181714C1]\]. Globally, breast cancer is the most frequently diagnosed cancer in women; it affects about 12% of women worldwide \[[@RSOS181714C2]\]. Saudi Arabia is no exception, where breast cancer is most commonly prevalent. It accounts for about 22% of all new cancers in women that are ranked first figures \[[@RSOS181714C3]\]. There is a group of novel drugs that specifically target gene changes in cancer cells that help the cells grow or spread. Tyrosine kinases (TKs) are important targets because of their important role in the modulation of growth factor signalling \[[@RSOS181714C4]\]. Controlling the activity of TK in the cell regulates many vital processes such as cell cycle, proliferation and cell death \[[@RSOS181714C5]\].

Cyclin-dependent kinases 4 and 6 (CDK4/6), as a class of tyrosine kinase inhibitor (TKI), play a crucial role in cell proliferation. When CDK4/6 pathway is dysregulated, it leads to an implication in breast cancer biology \[[@RSOS181714C6]\]. There are three highly selective CDK4/6 inhibitors that have been approved for breast cancer therapy: Palbociclib, Ribociclib and Abemaciclib (ABC) (Verzenio^®^) \[[@RSOS181714C7]\]. ABC ([figure 1](#RSOS181714F1){ref-type="fig"}) is the third agent in this class, which was approved in September 2017 by the Food and Drug Administration (FDA), either in combination with fulvestrant for women or as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer. Lately, in February 2018, FDA approved ABC with an aromatase inhibitor as the first-line endocrine-based therapy for metastatic breast cancer. The most frequent side effects of the drug were diarrhoea, which occurred in approximately 80% of patients, neutropenia, fatigue, infections, nausea, abdominal pain, anaemia, vomiting, alopecia, decreased appetite and leukopenia \[[@RSOS181714C8]\]. Figure 1.ABC chemical structure.

Our group previously studied reactive metabolite formations of some TKI drugs. The current work proved that ABC formed three reactive intermediates through a specific bioactivation pathway. KCN was used as a trapping agent to capture the formed reactive metabolites and the bioactivation pathways were characterized \[[@RSOS181714C8]--[@RSOS181714C12]\]. The chemical structures of ABC contain *N*-ethyl piperazine ring. This group is expected to undergo metabolism generating reactive iminium intermediates that can be trapped by KCN forming cyano adducts. Oxidation at a carbon alpha to an N-substituted piperazine ring is known to result in iminium ions, which are considered hard electrophiles and can be trapped by cyanide anions to form cyano adducts. The N-substituted piperazine partial structures become bioactivated and subsequently trapped by the nucleophilic cyanide anion. The reactive intermediates were postulated as imine and imine-carbonyl conjugate (α,β-unsaturated) structures on the piperazine ring. Bioactivation of the N-substituted piperazine partial structure, which can be characterized and detected using tandem mass spectrometry (LC--MS/MS), is a possible explanation for reported idiosyncratic toxicity \[[@RSOS181714C13]--[@RSOS181714C16]\].

Iminium intermediates initiate several toxic side effects through previously reported mechanisms as in the case of brigatinib and ponatinib that bind covalently to a DNA base \[[@RSOS181714C9],[@RSOS181714C17]\]. Knowing the electrodeficient bioactive centre in ABC structure helped in making targeted modifications to improve its safety and retain its efficacy. ABC rat liver microsome (RLM) incubation resulted in the identification of nine *in vitro* phase I metabolites and three cyano conjugates, and the proposed reactions involved include reduction, oxidation, hydroxylation and cyanide addition.

2.. Chemicals and methods {#s2}
=========================

2.1.. Chemicals {#s2a}
---------------

All chemicals are described in [table 1](#RSOS181714TB1){ref-type="table"}. RLMs were made in house using Sprague-Dawley rats following previously reported methods \[[@RSOS181714C9],[@RSOS181714C17]--[@RSOS181714C19]\]. The experimental design for animal work was approved by the University\'s Ethics Review Committee. Table 1.List of chemicals and materials.namesourceAbemaciclibMed. Chem. Express (NJ, USA)acetonitrile (HPLC grade), ammonium formate, potassium cyanide and formic acidSigma-Aldrich (USA)water (HPLC grade)Milli-Q plus filtration system (USA)rats (Sprague-Dawley)King Saud University experimental animal care center (Saudi Arabia)

2.2.. Chromatographic conditions {#s2b}
--------------------------------

An Agilent 6410 QQQ equipped with an ESI coupled to an Agilent 1200 HPLC was used. The liquid and mass chromatographic parameters were adjusted for each drug. ABC and its metabolites were produced in the collision cell by CID. The optimized conditions for chromatographic resolution of incubation mixture extract are given in [table 2](#RSOS181714TB2){ref-type="table"}. Table 2.Chromatographic parameters of the proposed LC--MS/MS methodology.liquid chromatographymass spectrometryRRLCAgilent 1200 seriesmass spectrometerAgilent 6410 QQQmobile phaseA: 0.1% formic acidESI sourcepositive ESIB: ACNN~2~ of low purity as drying gas: At flow rate of 12 l min^−1^ and 60 psi pressureflow rate: 0.25 ml min^−1^run time: 75 minAgilent Zorbax eclipse plus C~18~ columnL150 mmESI temperature: 350°CID2.1 mmcapillary voltage: 4000 VPS3.5 µmgas inside collision cellN~2~ of high purityT22 ± 1°Cdetection modesMS scan and PIelution systemtime in minutes% ACNdrugABC and its *in vitro* and reactive metabolites0555fragmentationfragmentor voltage (FV): 135 V3060collision energy (CE): 20 eV4090455

2.3.. RLM incubations {#s2c}
---------------------

ABC was incubated at 20 µM with 1 mg ml^−1^ RLMs, 1 mM NADPH, 1 mM KCN and 50 mM Na/K phosphate buffer (pH 7.4) containing 3.3 mM MgCl~2~. The mixtures were incubated at 37°C in a shaking water bath for 60 min before the metabolic reactions were terminated using protein precipitation by adding 2 ml of ice-cold ACN followed by centrifugation at 9000 g for 10 min at 4°C. The supernatants were removed to clean vials then evaporated to dryness, reconstituted in the mobile phase and analysed by the LC/MS system \[[@RSOS181714C8],[@RSOS181714C12],[@RSOS181714C17],[@RSOS181714C20]\]. Two controls were done in the absence of NADPH or RLMs to confirm that ABC phase I metabolites were metabolically formed.

2.4.. Characterization of ABC reactive intermediates in *in vitro* metabolic reactions {#s2d}
--------------------------------------------------------------------------------------

The same RLM metabolic incubation with ABC, previously described in §2.3, was repeated but in addition to 1.0 mM KCN to trap reactive iminium intermediates. This experiment was repeated three times to confirm the results and support our conclusions. Two controls were done in the absence of NADPH or KCN to confirm that cyano adducts are formed due to metabolic bioactivation.

2.5.. Identification of ABC reactive metabolites {#s2e}
------------------------------------------------

MS scan and extracted ion chromatogram (EIC) detection modes were used to characterize and locate metabolites in the incubation mixtures, while product ion (PI) was used to identify ABC *in vitro* metabolites and adducts of reactive intermediates formed in ABC metabolism. Locating metabolites in metabolic mixture extract chromatogram was performed by EIC of *m/z* of the supposed ABC metabolites.

3.. Results and discussion {#s3}
==========================

3.1.. PI study of ABC {#s3a}
---------------------

ABC chromatographic peak appears at 24.0 min in PI chromatogram ([figure 2](#RSOS181714F2){ref-type="fig"}*a*). Collision-induced dissociation (CID) of ABC at *m/z* 507 generates one fragment ion (FI) at *m/z* 399 by the loss of ethyl piperazine moiety ([figure 2](#RSOS181714F2){ref-type="fig"}*b* and [scheme 1](#RSOS181714F12){ref-type="fig"}). Figure 2.ABC PI chromatogram (*a*) and ABC PI MS spectrum (*b*). Scheme 1.PIs of ABC.

3.2. Identification of *in vitro* and reactive ABC metabolites {#s3b}
--------------------------------------------------------------

After the purification and extraction of ABC RLM incubations, 15 µl was injected into LC--MS/MS. ABC incubation led to the identification of nine *in vitro* phase I metabolites and three cyano adducts, and the proposed reactions involved include reduction, oxidation, hydroxylation and cyanide addition ([table 3](#RSOS181714TB3){ref-type="table"}). All these metabolites were formed in all incubations when repeated three times; this confirmed the validity of the used method. These results were confirmed by the absence of identified phase I metabolites and cyano adducts in all controls. Table 3.Identified *in vitro* and cyano adducts of ABC.MS scanMS^2^ product ions*t*~R~ (min)proposed phase 1 metabolic reactionABC50739323.9*In vitro* ABC metabolismABC493a493378.822.8demethylationABC493b493378.925.8demethylationABC509509395.1, 50924.3reductionABC521521365, 406.5, 52128.8methyl oxidationABC523a52339323.2ethyl hydroxylationABC523b523130, 393, 421, 495, 52326.5piperazine hydroxylationABC525a525395.123.32hydroxylation and reductionABC525b525395.126.4hydroxylation and reductionABC537537392.530.74hydroxylation and oxidationcyano adductsABC532a532392.926.5cyanide additionABC532b53239337.2cyanide additionABC54854839329.36hydroxylation and cyanide addition

### 3.2.1.. Identification of ABC493a and ABC493b phase I metabolites of ABC {#s3b1}

ABC493a and ABC493b chromatographic peaks appear at 22.8 and 25.8 min, respectively, in PI chromatogram ([figure 3](#RSOS181714F3){ref-type="fig"}*a*). CID of AB493 generates one FI at *m/z* 379 ([figure 3](#RSOS181714F3){ref-type="fig"}*b*,*c*). Comparing with PIs of ABC, a decrease of 14 *m/z* units was identified, which indicates that demethylation metabolic reaction occurred in benzimidazole ring ([scheme 2](#RSOS181714F13){ref-type="fig"}). Figure 3.ABC493 PI chromatogram (*a*), ABC493a PI MS spectrum (*b*) and ABC493b PI MS spectrum (*c*). Scheme 2.PIs of ABC493a and ABC493b.

### 3.2.2.. Identification of ABC509 phase I metabolite of ABC {#s3b2}

ABC509 chromatographic peak appears at 24.3 min in PI chromatogram ([figure 4](#RSOS181714F4){ref-type="fig"}*a*). CID of ABC509 generates one FI at *m/z* 395 ([figure 4](#RSOS181714F4){ref-type="fig"}*b*). Compared with PIs of ABC, an increase of 2 *m/z* units was identified, which indicates that reduction metabolic reaction occurred in benzimidazole ring ([scheme 3](#RSOS181714F14){ref-type="fig"}). Figure 4.ABC509 PI chromatogram (*a*) and ABC509 PI MS spectrum (*b*). Scheme 3.PIs of ABC509.

### 3.2.3.. Identification of ABC521 phase I metabolite of ABC {#s3b3}

ABC521 chromatographic peak appears at 28.7 min in PI chromatogram ([figure 5](#RSOS181714F5){ref-type="fig"}*a*). CID of ABC521 generates two FIs at *m/z* 407 and *m/z* 365 ([figure 5](#RSOS181714F5){ref-type="fig"}*b*). Compared with PIs of ABC, an increase of 14 *m/z* units was identified, which indicates that oxidation metabolic reaction occurred in benzimidazole ring ([scheme 4](#RSOS181714F15){ref-type="fig"}). Figure 5.ABC521 PI chromatogram (*a*) and ABC521 PI MS spectrum (*b*). Scheme 4.PIs of ABC521.

### 3.2.4.. Identification of ABC523a and ABC523b phase I metabolites of ABC {#s3b4}

ABC523a and ABC523b chromatographic peaks appeared at 23.2 and 26.4 min, respectively, in PI chromatogram ([figure 6](#RSOS181714F6){ref-type="fig"}*a*). CID of ABC523a generates one FI at *m/z* 393 ([figure 6](#RSOS181714F6){ref-type="fig"}*b*). CID of ABC523b generates three FIs at *m/z* 495, *m/z* 393 and *m/z* 130 ([figure 6](#RSOS181714F6){ref-type="fig"}*c*). Compared with PIs of ABC, an increase of 16 *m/z* units was identified, which indicates that hydroxylation metabolic reaction occurred in *N*-ethyl piperazine ring ([scheme 5](#RSOS181714F16){ref-type="fig"}). Figure 6.ABC523 PI chromatogram (*a*), ABC523a PI MS spectrum (*b*) and ABC523b PI MS spectrum (*c*). Scheme 5.PIs of ABC523a and ABC523b.

### 3.2.5.. Identification of ABC525a and ABC525b phase I metabolites of ABC {#s3b5}

ABC525a and ABC525b chromatographic peaks appeared at 23.3 and 26.4 min, respectively, in PI chromatogram ([figure 7](#RSOS181714F7){ref-type="fig"}*a*). CID of ABC525 metabolites generates one FI at *m/z* 395 ([figure 7](#RSOS181714F7){ref-type="fig"}*b*,*c*). Compared with PIs of ABC, an increase of 18 *m/z* units was identified, which indicates that reduction metabolic reaction occurred in benzimidazole ring in addition to hydroxylation metabolic reaction that occurred in *N*-ethyl piperazine ring ([scheme 6](#RSOS181714F17){ref-type="fig"}). Figure 7.ABC525 PI chromatogram (*a*), ABC525a PI MS spectrum (*b*) and ABC525b PI MS spectrum (*c*). Scheme 6.PIs of ABC525a and ABC525b.

### 3.2.6.. Identification of ABC537 phase I metabolite of ABC {#s3b6}

ABC537 chromatographic peak appears at 30.7 min in PI chromatogram ([figure 8](#RSOS181714F8){ref-type="fig"}*a*). CID of ABC537 generates one FI at *m/z* 393 ([figure 8](#RSOS181714F8){ref-type="fig"}*b*). Compared with PIs of ABC, an increase of 30 *m/z* units was identified, which indicates hydroxylation and oxidation metabolic reactions occurred in *N*-ethyl piperazine ring ([scheme 7](#RSOS181714F18){ref-type="fig"}). Figure 8.ABC537 PI chromatogram (*a*) and ABC537 PI MS spectrum (*b*). Scheme 7.PIs of ABC537.

### 3.2.7.. Identification of ABC532a and ABC532b cyano adducts of ABC {#s3b7}

ABC532a and ABC532b chromatographic peaks appeared at 26.8 and 37.2 min, respectively, in PI chromatogram ([figure 9](#RSOS181714F9){ref-type="fig"}*a*). CID of ABC532 metabolites generates one FI at *m/z* 393 ([figure 9](#RSOS181714F9){ref-type="fig"}*b*,*c*). Compared with PIs of ABC, PI at *m/z* 393 indicates that all metabolic changes occurred in *N*-ethyl piperazine ring. An increase of 25 *m/z* units indicates that cyano addition occurred in *N*-ethyl piperazine ring ([scheme 8](#RSOS181714F19){ref-type="fig"}). Figure 9.ABC532 PI chromatogram (*a*), ABC532a PI MS spectrum (*b*) and ABC532b PI MS spectrum (*c*). Scheme 8.PIs of ABC532a and ABC532b.

### 3.2.8.. Identification of ABC548 cyano adduct of ABC {#s3b8}

ABC548 chromatographic peak appears at 29.4 min in PI chromatogram ([figure 10](#RSOS181714F10){ref-type="fig"}*a*). CID of ABC548 generates one FI at *m/z* 393 ([figure 10](#RSOS181714F10){ref-type="fig"}*b*). Compared with PIs of ABC, PI at *m/z* 393 indicates that all metabolic changes occurred in *N*-ethyl piperazine ring. An increase of 41 *m/z* units indicates that hydroxylation and cyano addition occurred in *N*-ethyl piperazine ring ([scheme 9](#RSOS181714F20){ref-type="fig"}). Figure 10.ABC548 PI chromatogram (*a*) and ABC548 PI MS spectrum (*b*). Scheme 9.PIs of ABC548.

3.3.. Supposed pathways of bioactivation of ABC {#s3c}
-----------------------------------------------

[Scheme 10](#RSOS181714F21){ref-type="fig"} shows the different pathways for bioactivation of ABC. The formation of ABC532a, ABC532b and ABC548 cyanide adducts confirmed the formation of iminium intermediates in piperazine ring metabolism. Hydroxylation of piperazine ring in ABC followed by dehydration resulted in the generation of iminium ion intermediates that are unstable and reactive that can be trapped by cyanide-forming stable adduct which can be detected in LC--MS/MS. The formation pathway of iminium intermediate and bioactivation mechanism of ABC was previously described with cyclic tertiary amine-containing drugs \[[@RSOS181714C10],[@RSOS181714C11],[@RSOS181714C17],[@RSOS181714C20]\]. Scheme 10.Proposed pathways for the iminium intermediate generation and trapping strategy.

4.. Conclusion {#s4}
==============

Three potential iminium reactive metabolites were detected and the bioactivation pathways were proposed ([figure 11](#RSOS181714F11){ref-type="fig"}). Nine *in vitro* phase I metabolites were identified. The findings of potentially reactive intermediates of these drugs may give a deeper understanding of their adverse effects. Further drug discovery studies in ABC structure can shed more light on the possibility of blocking or reducing the formation of reactive intermediates by introducing alkyl substituents or isosteric replacement to the alpha position of the piperazine partial moiety which would probably block or interrupt enzymatic oxidation/hydroxylation on α-carbon atoms. This study opens the way for new drug development with more safety profile. Figure 11.*In vitro* metabolic pathways and bioactivation centres of ABC.
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